Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

msh id	COM:INTELLIATX
symbol	NTLA
name	Intellia Therapeutics, Inc.
homepage url	https://www.intelliatx.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	526
crunchbase url	-
linkedin url	-
founders	-

market cap	2.23B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.08
growth cost of revenue	0.19
growth depreciation and amortization	-0.33
growth ebitda	-0.14
growth ebitda ratio	-0.64
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.29
growth gross profit	-0.39
growth gross profit ratio	-0.12

COM:INTELLIATX

Intellia Therapeutics

Last Close

13.12

21/11 19:09

Market Cap

2.23B

Beta: -

Volume Today

2.08M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	551.57M
cost of revenue	551.57M
depreciation and amortization	8.98M
ebitda	-506.22M
ebitda ratio	-13.95
eps	-5.42
eps diluted	-5.42
operating expenses	551.57M
operating income	-515.29M
operating income ratio	-14.21

accounts receivables	-32.69M
capital expenditure	-13.99M
cash at beginning of period	535.46M
cash at end of period	240.35M
inventory	-
working capital ttm	801.54M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-